Research has come a long way, but RA is still a
complex disease to treat

Up to 25% of RA patients in industrialised countries will not achieve low disease activity on biologic or synthetic DMARDs.1 While many patients will achieve ACR20, over 75% of MTX-IR or TNF-IR patients may not achieve low disease activity (ie, ACR 70) on targeted therapies.1
According to treat-to-target recommendations, the absence of remission or low disease activity requires a change in therapy.1 However, response to targeted therapies diminishes with every subsequent line of treatment.2
In RA, there is an increase in rates of serious infections from less than 1/1000 PYs in the healthy population to 5/1000 PYs in people with RA.3 Patients with RA also have an increased risk of cardiovascular comorbidities and mortality compared to the generalpopulation.4-6
Working to address unmet needs in RA


For news on the partnership’s continuing innovation in RA, subscribe here.
References: 1. Aletaha D, Smolen JS. JAMA. 2018;320(13):1360-1372. 2. Rendas-Baum R, et al. Arthritis Res Ther. 2011;13(1):R25. 3. Ravanbod H, et al. J Immunol Infect Inflam Dis. 2017;2(3):1-9. 4. Crowson CS, et al. Am Heart J. 2013;166(4):622-628.e1. 5. Kaplan MJ. Rheum Dis Clin North Am. 2010;36(2): 405-426. 6. Aviña-Zubieta JA, et al. Arthritis Rheum. 2008;59(12):1690-1697.